Literature DB >> 9687400

Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients.

G Gatti1, P Papa, D Torre, M Andreoni, A Poggio, M Bassetti, P Marone.   

Abstract

Rifabutin pharmacokinetics were studied by the population approach (NONMEM) with 40 human immunodeficiency virus-infected patients receiving rifabutin at different doses for prophylaxis or therapy of mycobacterial infections. A two-compartment open model with first-order absorption was used as the structural pharmacokinetic model. Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters). The distribution and elimination half-lives were 1.24 and 25.4 h, respectively. The covariates tested for influence on CL/F and Vp/F were sex, age, weight, height, body surface area, tobacco smoking, drug addiction, alanine aminotransferase levels, creatinine clearance, total protein, bilirubin, numbers of CD4(+) cells, presence of diarrhea, cachexia index, rifabutin use (prophylaxis versus therapy), rifabutin dose, study site, and the concomitant administration of clarithromycin, fluconazole, phenobarbital, ciprofloxacin, azithromycin, or benzodiazepines. The only statistically significant effects on rifabutin pharmacokinetic parameters were a 27% decrease in Vp/F due to the concomitant administration of azithromycin and a 39% increase in Vp/F due to tobacco smoking. Such effects may be considered clinically unimportant. Our results confirm the lack of a correlation of rifabutin pharmacokinetic parameters with parameters of disease progression and gastrointestinal function. Also, the lack of a correlation with covariates which were previously found to be significant, such as concomitant fluconazole and clarithromycin use, may suggest that the effect of such covariates may be less important in the real clinical setting, in which several concomitant factors may influence pharmacokinetic parameters, with an overall effect of no apparent correlation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687400      PMCID: PMC105726     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Rifabutin absorption in humans: relative bioavailability and food effect.

Authors:  P K Narang; R C Lewis; J R Bianchine
Journal:  Clin Pharmacol Ther       Date:  1992-10       Impact factor: 6.875

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.

Authors:  E Perucca; R Grimaldi; G M Frigo; A Sardi; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Intraphagocytic penetration of antibiotics.

Authors:  P Van der Auwera; T Matsumoto; M Husson
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

5.  Malabsorption of antimycobacterial medications.

Authors:  C A Peloquin; A A MacPhee; S E Berning
Journal:  N Engl J Med       Date:  1993-10-07       Impact factor: 91.245

6.  Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients.

Authors:  G Gatti; M Merighi; J Hossein; S Travaini; R Casazza; M Karlsson; M Cruciani; D Bassetti
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

7.  Pharmacokinetics of rifabutin.

Authors:  M H Skinner; M Hsieh; J Torseth; D Pauloin; G Bhatia; S Harkonen; T C Merigan; T F Blaschke
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

8.  Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

Authors:  S D Nightingale; D W Cameron; F M Gordin; P M Sullam; D L Cohn; R E Chaisson; L J Eron; P D Sparti; B Bihari; D L Kaufman
Journal:  N Engl J Med       Date:  1993-09-16       Impact factor: 91.245

9.  Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease.

Authors:  S M Gordon; C R Horsburgh; C A Peloquin; J A Havlik; B Metchock; L Heifets; J E McGowan; S E Thompson
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

10.  Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS.

Authors:  G Gatti; J Flaherty; J Bubp; J White; M Borin; J Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  7 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations.

Authors:  Christian Bustamante; Rodrigo Ochoa; Claudia Asela; Carlos Muskus
Journal:  J Comput Aided Mol Des       Date:  2019-10-14       Impact factor: 3.686

Review 3.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

4.  Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study.

Authors:  S Mouly; G Aymard; J P Tillement; C Caulin; J F Bergmann; S Urien
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

5.  Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.

Authors:  Stefanie Hennig; Suhashni Naiker; Tarylee Reddy; Deirdre Egan; Tracy Kellerman; Lubbe Wiesner; Andrew Owen; Helen McIlleron; Alexander Pym
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

6.  Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.

Authors:  Stefanie Hennig; Elin M Svensson; Ronald Niebecker; P Bernard Fourie; Marc H Weiner; Stefano Bonora; Charles A Peloquin; Keith Gallicano; Charles Flexner; Alex Pym; Peter Vis; Piero L Olliaro; Helen McIlleron; Mats O Karlsson
Journal:  J Antimicrob Chemother       Date:  2016-01-31       Impact factor: 5.790

Review 7.  Pharmacokinetics of drugs in cachectic patients: a systematic review.

Authors:  Katja Trobec; Mojca Kerec Kos; Stephan von Haehling; Jochen Springer; Stefan D Anker; Mitja Lainscak
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.